Cite
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
MLA
A. V. Blokhina, et al. “PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center.” Racionalʹnaâ Farmakoterapiâ v Kardiologii, vol. 17, no. 6, Jan. 2022, pp. 808–15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....85088fc73f848909dbc226c4bb17e75d&authtype=sso&custid=ns315887.
APA
A. V. Blokhina, A. I. Ershova, A. S. Limonova, O. V. Kopylova, A. N. Meshkov, & O. M. Drapkina. (2022). PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center. Racionalʹnaâ Farmakoterapiâ v Kardiologii, 17(6), 808–815.
Chicago
A. V. Blokhina, A. I. Ershova, A. S. Limonova, O. V. Kopylova, A. N. Meshkov, and O. M. Drapkina. 2022. “PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center.” Racionalʹnaâ Farmakoterapiâ v Kardiologii 17 (6): 808–15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....85088fc73f848909dbc226c4bb17e75d&authtype=sso&custid=ns315887.